Company / Total Assets
Monopar Therapeutics Total Assets History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$140.7M
FY2025
5-year range
$7.3M / $140.7M
FY2021-FY2025
Trend
+133.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Assets has fluctuated over the past 6 years, ranging from $7M in FY2018 to $141M in FY2025.
Based on SEC 10-K filings.
$141M in FY2025.
Improved from $7M to $141M over the past 2 years.
Total Assets over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, total assets increased 133.4% year-over-year.
- Lowest total assets in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 19.82 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $140.7M | +133.4% |
| FY2024 | $60.3M | +720.8% |
| FY2023 | $7.3M | -45.0% |
| FY2019 | $13.4M | +82.5% |
| FY2018 | $7.3M | -26.3% |
| FY2017 | $9.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026